Maharashtra, India

Anand Atul Bade

This inventor holds 1 USPTO granted patent. Top assignee: Fdc Limited. Active years: 2012.


Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Anand Atul Bade

Introduction

Anand Atul Bade is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceuticals through his innovative research and development efforts. His work focuses on the preparation of complex chemical compounds that have potential therapeutic applications.

Latest Patents

Anand Atul Bade holds a patent for a process related to the preparation of 5,6-dihydro-4H-4(S)-ethylamino-6(S)-methylthieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide and its salt. The patent describes a method for resolving (cis,trans)5,6-dihydro-4H-4-ethylamino-6-methylthieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide using dibenzoyl-L-tartaric acid monohydrate or di-p-toluoyl-L-tartaric acid monohydrate as a chiral resolving agent in the presence of methanol. This process results in the production of a hemitartarate salt with a high degree of purity, which can be further converted into its pharmaceutically acceptable salts, preferably hydrochloride salt.

Career Highlights

Anand Atul Bade is associated with FDC Limited, where he applies his expertise in pharmaceutical chemistry. His work has contributed to advancements in drug formulation and development, showcasing his commitment to improving healthcare solutions.

Collaborations

Anand has collaborated with notable colleagues such as Anand Mohan Chandavarkar and Rajaram Uday Bapat. These collaborations have fostered a productive environment for innovation and research within the pharmaceutical industry.

Conclusion

Anand Atul Bade's contributions to the field of pharmaceuticals through his innovative patent and collaborative efforts highlight his role as a significant inventor. His work continues to impact the development of effective therapeutic agents.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…